In this model, baseline levels of CD4 SP + sp 4 7 SP + sp T cells, CRP levels at baseline, smoking history, baseline levels of CD4 SP + sp E 7 SP + sp T cells and CD4 SP + sp 4 1 SP + sp T cells were the top 5 features selected. Despite the growing number of treatments approved for inflammatory bowel disease (IBD), patient outcomes can still be unsatisfactory due to highly variable response rates.1 Vedolizumab, first alternative biological for anti-tumour necrosis factor (TNF) in IBD management, targets 4 7 integrin heterodimers on circulatory T cells and inhibits their binding to mucosal addressin cell adhesion molecule 1 (MAdCAM-1). [Extracted from the article]